Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer

被引:26
|
作者
Erber, Ramona [1 ]
Stoehr, Robert [1 ]
Herlein, Stefanie [1 ]
Giedl, Claudia [1 ]
Rieker, Ralf Joachim [1 ]
Fuchs, Florian [2 ]
Ficker, Joachim H. [3 ]
Hartmann, Arndt [1 ]
Veltrup, Elke [4 ]
Wirtz, Ralph M. [4 ,5 ]
Brueckl, Wolfgang M. [3 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Univ Hosp, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Med Gastroenterol Pneumonol & Endocrinol 1, Univ Hosp, Erlangen, Germany
[3] Paracelsus Med Univ Nuernberg, Gen Hosp Nuernberg, Dept Resp Med Allergol & Sleep Med, Nurnberg, Germany
[4] STRATIFYER Mol Pathol GmbH, Cologne, Germany
[5] St Elizabeth Hosp, Inst Pathol, Cologne, Germany
关键词
PD-L1; PD-1; NSCLC; lung cancer; pembrolizumab; nivolumab; E1L3N; 28-8; immunohistochemistry; EBUS-TBNA; mRNA; SQUAMOUS-CELL; NIVOLUMAB; DOCETAXEL;
D O I
10.21873/anticanres.12137
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immunohistochemical (IHC) assessment of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) has become important since the development of anti-PD-1/-PD-L1 directed drugs. Various PD-L1 antibodies and cut-offs have been used in different trials to predict response to these drugs, thus comparison of those studies is difficult. We compared PD-L1 mRNA expression measured by RT-qPCR with PD-L1 protein expression evaluated by IHC. Moreover, we investigated the impact of different tumour tissue acquisition methods on the reliability of PD-L1 measurement techniques. Materials and Methods: NSCLC cases (N=22), including n=9 mediastinal lymph node biopsies acquired by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and n=5 metastases, were evaluated prospectively for PD-L1 protein on tumor cells (TC) and immune cells (IC) using E1L3N and 28-8 antibodies and PD-L1 mRNA using the CheckPoint TYPER (R) assay. Results: In primary NSCLC tissues, agreement between PD-L1 mRNA and TC staining using the 28-8 antibody was excellent (kappa=0.85, p=0.0002). Comparing both PD-L1 antibodies against each other showed a kappa value of 0.58 (p=0.0106). In EBUS-TBNA, PD-L1 mRNA correlated perfectly with the 28-8 antibody (kappa=1.0, p=0.0023). PD-L1 mRNA levels significantly differed when comparing 28-8 TC staining of tumours >49% with 1-49% and 0% (p=0.0040; p=0.0081, respectively). In metastatic lesions, differences between PD-L1 mRNA and IHC became apparent (kappa=0.2, p=0.2525). Conclusion: Testing of PD-L1 mRNA and 28-8 IHC showed an excellent agreement in NSCLC samples including mediastinal lymph node biopsies. Since PD-L1 expression in >50% TC detected by 28-8 IHC can be reliably detected by RT-qPCR, quantitative PD-L1 mRNA determination should be considered as an alternative to IHC as there is no interobserver variability in RNA results.
引用
收藏
页码:6771 / 6778
页数:8
相关论文
共 50 条
  • [1] Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Hersom, Maria
    Jorgensen, Jan T.
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 9 - 16
  • [2] PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
    Hirsch, Fred R.
    McElhinny, Abigail
    Stanforth, Dave
    Ranger-Moore, James
    Jansson, Malinka
    Kulangara, Karina
    Richardson, William
    Towne, Penny
    Hanks, Debra
    Vennapusa, Bharathi
    Mistry, Amita
    Kalamegham, Rasika
    Averbuch, Steve
    Novotny, James
    Rubin, Eric
    Emancipator, Kenneth
    McCaffery, Ian
    Williams, J. Andrew
    Walker, Jill
    Longshore, John
    Tsao, Ming Sound
    Kerr, Keith M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 208 - 222
  • [3] Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis
    Zhang, Binbin
    Liu, Yi
    Zhou, Sijing
    Jiang, Huihui
    Zhu, Ke
    Wang, Ran
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [4] PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
    Munari, Enrico
    Zamboni, Giuseppe
    Marconi, Marcella
    Sommaggio, Marco
    Brunelli, Matteo
    Martignoni, Guido
    Netto, George J.
    Moretta, Francesca
    Mingari, Maria Cristina
    Salgarello, Matteo
    Terzi, Alberto
    Picece, Vincenzo
    Pomari, Carlo
    Lunardi, Gianluigi
    Cavazza, Alberto
    Rossi, Giulio
    Moretta, Lorenzo
    Bogina, Giuseppe
    ONCOTARGET, 2017, 8 (52): : 90123 - 90131
  • [5] Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer
    Montero, M. Angeles
    Aricak, Ozan
    Kis, Lorand
    Yoshikawa, Akira
    De Petris, Luigi
    Grundberg, Oscar
    Pham, Hoa H. N.
    Roden, Anja C.
    Fukuoka, Junya
    Attanoos, Richard
    Guijarro, Ricardo
    Alarcon, Felix
    Lindstrom, Kati
    Ortiz-Villalon, Cristian
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2021, 51
  • [6] Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
    Dori, Shani Ben
    Aizic, Asaf
    Sabo, Edmond
    Hershkovitz, Dov
    LUNG CANCER, 2020, 147 : 91 - 98
  • [7] The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer
    Kim, Gun-Jik
    Lee, Jae-Ho
    Park, Won-Jin
    Lee, Hye-Won
    Hwang, Il-Seon
    Lee, Deok Heon
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2019, 49 (03) : 317 - 323
  • [8] Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
    Velcheti, Vamsidhar
    Patwardhan, Pallavi D.
    Liu, Frank Xiaoqing
    Chen, Xin
    Cao, Xiting
    Burke, Thomas
    PLOS ONE, 2018, 13 (11):
  • [9] PD-L1 immunohistochemistry in patients with non-small cell lung cancer
    Jotatsu, Takanobu
    Oda, Keishi
    Yatera, Kazuhiro
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2127 - S2129
  • [10] PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
    Scheel, Andreas H.
    Ansen, Sascha
    Schultheis, Anne M.
    Scheffler, Matthias
    Fischer, Rieke N.
    Michels, Sebastian
    Hellmich, Martin
    George, Julie
    Zander, Thomas
    Brockmann, Michael
    Stoelben, Erich
    Groen, Harry
    Timens, Wim
    Perner, Sven
    von Bergwelt-Baildon, Michael
    Buettner, Reinhard
    Wolf, Juergen
    ONCOIMMUNOLOGY, 2016, 5 (05):